Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Leads Biolabs Grants License for Inhaled Delivery of its Immunotherapies

publication date: May 16, 2019

Leads Biolabs of Maryland, a fully-owned subsidiary of a US-China JV, Nanjing Leads Biolabs, granted Pneuma Respiratory an exclusive license to develop Leads' panel of immuno-oncology mAbs and fusion protein molecules for pulmonary delivery. Pneuma, based in North Carolina, has developed a proprietary breath-activated digital inhaler. Using the inhaler, Pneuma will develop Leads' immuno-oncology therapies for pulmonary delivery to treat oncologic or immune-mediated lung diseases. Leads has developed a portfolio of more than ten novel mono or bispecific antibodies for cancer immunotherapy and other major diseases. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China